NBS NeoStem, Inc. Announces the Redemption of the

New Post Public Reply Private Reply Replies (0) Message Board

Oct 17, 2012 at 9:44 AM

NBS >>> NeoStem, Inc. Announces the Redemption of the Outstanding 7% Series E Preferred Stock

2012-10-17 07:30 ET - News Release

NEW YORK, Oct. 17, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that it will redeem all outstanding shares of its Series E 7% Senior Convertible Preferred Stock ("Series E Preferred Stock").

On October 10, 2012, the Company gave notice to its Series E Preferred Stockholders that it is redeeming all of the outstanding shares of Series E Preferred Stock for an aggregate redemption price of $3.4 million, $2.5 million of which was funded by money placed into escrow when the Series E Preferred stock was issued in November 2010.

"We are pleased that we have been able to redeem this $10 million investment in full over a two year period. Equal to our focus on cell therapy product development and expanding our PCT contract development and manufacturing operations, we are committed to improving our balance sheet. Through the redemption of the Series E Preferred Stock, we will remove a significant overhang and simplify NeoStem's capital structure. The redemption of the Series E Preferred Stock is another example of a step taken by us to improve Common Stockholder value," said Dr. Robin Smith, Chairman and CEO of NeoStem. "We look forward to continued execution on our near term business strategy, including the forthcoming closing of the divestiture of our Erye China pharmaceutical subsidiary."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midlife ADHD in Women: New Challenges and Solutions

ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...

Give Lively & Change Simplify CA Nonprofit Compliance

A Fresh Wind Blowing for California Nonprofits So, here's a twist in the nonprofit world that's stirring the pot just right. Give Lively and Change have partnered up to tackle the thorny issue of regulatory compliance in California. It's a big win for the nonprofits looking to keep fundraising through Give Lively without getting tangled in the bureaucratic web spun up by...

EFSI Shareholders on Alert Amid M&A Deal Scrutiny

Eagle Financial Services Under the Microscope A buzz is picking up in the world of mergers and acquisitions, and this time, it's Eagle Financial Services, Inc. (NASDAQ: EFSI) caught in the crosshairs. What's the chatter all about? Well, it looks like Juan Monteverde and his crew over at Monteverde & Associates PC have set their sights on Eagle's proposed sale to John...

Job Market Shifts: Adaptation vs. Fairness Dilemma

The Chameleon Effect in Today's Job Market Walk into any open-space office these days, and you'll see faces plastered with composed, work-ready smiles—faces that might not look so familiar outside those walls. The modern workplace has draped its cloak over individual personalities, with the mighty pressure to 'fit in' often forcing a change in how folks present...

Push Notification Security Transforms Healthcare IT Support

Cutting the Fat on IT Help Desk Bottlenecks Healthcare IT teams are fighting an uphill battle with password resets, a mundane task consuming up to half of all help desk calls. It's like trying to stop a leaking dam with duct tape. For health systems, these calls aren't just a minor annoyance—they're a full-fledged budget hog. Try telling a CIO that an agent-friendly...

Maurices Strengthens Position with Key Refinancing Deal

Maurices' Bold Financial Maneuver When a retailer like Maurices, with its near-century-long history, decides to play in the financial arena, it sure makes my ears perk up. This Duluth-based women's fashion retailer isn't just dipping its toes in—it's executing a full-blown refinancing blitzkrieg and coming out stronger. Announcing the completion of its refinancing plan...

Global Communication Works Opens SignlLabs™ AI Licensing

AI Signaling Moves Beyond GCW's Own Clients Remember when we first looked at GCW's SignlLabs and the idea of helping brands show up inside ChatGPT, Gemini, Claude, Copilot and Perplexity? Well, Global Communication Works is taking the next step. Instead of keeping its AI Signaling playbook inside the agency walls, GCW is now opening SignlLabs up for licensing

CUBEX Lights Up Veterinary Care with Mini Essential

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

South Florida Donor Network Honors 52 Heroic Donors

A Heartfelt Tribute to Lifesavers You ever been to a gathering that reminds you how deeply human connections run? That's what happened at The Diplomat Beach Resort in Hollywood. South Florida Donor Network (SFDN) pulled together a ceremony honoring 52 donor heroes whose legacies beat strong through the recipients living thanks to their gifts. An Event Worth Attending...

Veho's Role in Redefining Beauty E-Commerce Delivery

Veho Grabs Headlines with BeautyMatter Awards Nod Here's something a bit off the beaten path: Veho's been tapping into new wells of opportunity in the e-commerce sector, and their latest accolade demonstrates just that. Named a finalist in the 2026 BeautyMatter Awards under the Logistics category, they're making noise in all the right circles. Beyond Boxes: Transforming...